The review of biologic therapy use for AA amyloidosis secondary to RA shows that TNF inhibitors, tocilizumab, abatacept, rituximab, and a JAK inhibitor can effectively prevent organ dysfunction and increase patient survival (Table 1). The gene discussed is TNF; the disease is AA amyloidosis.